Neuropathic Pain Clinical Trials 2023

Browse 79 Neuropathic Pain Medical Studies Across 165 Cities

9 Phase 3 Trial · 291 Neuropathic Pain Clinics

Reviewed by Michael Gill, B. Sc.
10 Neuropathic Pain Clinical Trials Near Me
Top Hospitals for Neuropathic Pain Clinical Trials
Image of Stanford University in California.
Stanford University
Stanford
3Active Trials
6All Time Trials for Neuropathic Pain
2016First Neuropathic Pain Trial
Image of University of Miami in Florida.
University of Miami
Miami
3Active Trials
4All Time Trials for Neuropathic Pain
2017First Neuropathic Pain Trial
Image of University of Minnesota in Minnesota.
University of Minnesota
Minneapolis
3Active Trials
5All Time Trials for Neuropathic Pain
2016First Neuropathic Pain Trial
Image of Massachusetts General Hospital in Massachusetts.
Massachusetts General Hospital
Boston
3Active Trials
6All Time Trials for Neuropathic Pain
2006First Neuropathic Pain Trial
Image of Rush University Medical Center in Illinois.
Rush University Medical Center
Chicago
2Active Trials
3All Time Trials for Neuropathic Pain
2019First Neuropathic Pain Trial
Top Cities for Neuropathic Pain Clinical Trials
Image of Boston in Massachusetts.
Boston
11Active Trials
Massachusetts General HospitalTop Active Site
Image of Houston in Texas.
Houston
10Active Trials
Expert PainTop Active Site
Neuropathic Pain Clinical Trials by Phase of TrialNeuropathic Pain Clinical Trials by Age Group
< 65 Neuropathic Pain Clinical Trials
3Active Neuropathic Pain Clinical Trials
Most Recent Neuropathic Pain Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Neuropathic Pain Clinical Trials
Treatment Name
Active Neuropathic Pain Clinical Trials
All Time Trials for Neuropathic Pain
First Recorded Neuropathic Pain Trial
Active DBS
2
2
2017
[18F]FTC-146
2
2
2018
Spinal Cord Stimulation
2
5
2014
Axon Therapy + CMM
1
1
2022
Qutenza (capsaicin) 8% topical system
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Neuropathic Pain
Treatment
Year
Sponsor
LY3526318
2022
Eli Lilly and Company
LX9211
2020
Lexicon Pharmaceuticals
ETX-018810
2020
Eliem Therapeutics (UK) Ltd.
Naloxone Hydrochloride 0.4 MG/ML
2020
Seema Capoor
Galcanezumab
2020
Duke University
BAY1817080
2020
Bayer
LY3016859
2020
Eli Lilly and Company
LX9211 high dose
2020
Lexicon Pharmaceuticals
NYX-2925 50 mg
2019
Aptinyx

What Are Neuropathic Pain Trials?

The most generally accepted definition of Neuropathic-Pain is pain started by a lesion or the somatosensory system (the system being damaged which provides the ability to feel sensations (pressure, pain, touch, position, movement, vibration, cold, or warmth).

The cause of neuropathic pain is damage to the nerves, which are on the outside of the spinal cord and brain, known as the peripheral nerves. Nerve functions may be altered, and the damaged nerve fibers send an incorrect signal to the pain centers.

Peripheral nerves spread throughout the body to the organs, arms, hands, torso, legs, feet, and others.

It is not always easy to trace the cause of Neuropathic-Pain, and hundreds of diseases have been observed to cause the condition.

Symptoms can include.

  • Spontaneous pain, which occurs for no cause.
  • Pain from previously benign sensations, such as smooth bedsheets or changes in temperature.
  • Sleep difficulties are caused by the change in sensations.

Why Is Neuropathic Pain Being Studied Through Clinical Trials?

It is estimated that up to 10% of the population suffers from symptoms that describe Neuropathic-Pain.

While it is not generally life-threatening or limiting, neuropathic pain can be a degenerative nerve condition with often poor outcomes in long-term treatment.

What Are The Types Of Treatments Available For Neuropathic Pain?

Treatments for most types of Neuropathic-Pain tend to focus on symptom management rather than a long-term cure.

The aims of treatment are.

  • Treatment of the underlying disease (e.g., Diabetes, Radiation To Reduce A Tumor Which Is Pressing On A Nerve, Alcoholism. Shingles, Stroke, Parkinson’s Disease, Multiple Sclerosis)
  • Pain management.
  • Improve the patient’s life quality.
  • To help the patient continue to be functional.

Examples Of Current Neuropathic Pain Trials

Three examples of current neuropathic-pain trials are listed below.

Testing The Efficacy Of Using Spinal Cord Stimulation To Reduce Neuropathic Pain

This study will focus on establishing how effective Spinal Cord Stimulation is in reducing Neuropathic-Pain. The study will also focus on how spinal cord stimulation affects the patient's psychological well-being regarding anxiety and depression.

Testing The Effect Of Methadone On Patients Suffering With Neuropathic Pain

Opioids are used as a third-line treatment to reduce Neuropathic-Pain. The typical Opioids used are Morphine, Tramadol, and Oxycodone. This study aims to test how effective Methadone is when prescribed in 5mg doses taken twice a day. Where necessary, up to 6 tablets doses will be administered per day.

Using Ketamine To Treat Neuropathic

This study aims to test the efficacy of using Ketamine for pain relief. The Ketamine will be tested against the following groups – Ketamine only, Ketamine, and magnesium sulfate against a placebo.

What Are Some Recent Breakthrough Clinical Trials For Neuropathic Pain?

Clinical trials focusing on neuropathic pain have been performed as follows.

2021: Spinal Cord Stimulation Therapy – Following successful clinical trials, the FDA has approved the use of the Intellis™ rechargeable neurostimulator and Vanta™ recharge-free neurostimulator.

2023: Using intraneural facilitation to treat patients who are suffering from type 2 diabetes mellitus. The trial confirmed that Intraneural Facilitation (INF) treatment is an effective method of restoring blood flow to damaged nerves and therefore reducing pain levels in patients suffering from diabetes mellitus.

Who Are Some Of The Key Opinion Leaders / Researchers Conducting Neuropathic Pain Clinical Trial Research?

Mark R. Bussell, DPT, Assistant Research Professor, Allied Health Studies, Loma Linda University.

Richard P. Winne Jr., MD Altair Health Spine & Wellness Center

Martyn Goulding, Ph.D. Salk Institute for Biological Studies, CA

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: September 28th, 2023

References1 Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. No abstract available. https://pubmed.ncbi.nlm.nih.gov/225887482 Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9. https://pubmed.ncbi.nlm.nih.gov/116907283 O'Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, Eccleston C. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021 Dec 2;12(12):CD013756. doi: 10.1002/14651858.CD013756.pub2. https://pubmed.ncbi.nlm.nih.gov/348544734 O'Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, Eccleston C. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021 Dec 2;12:CD013756. doi: 10.1002/14651858.CD013756.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/348544735 Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017 Mar 1;152(3):292-298. doi: 10.1001/jamasurg.2016.4952. https://pubmed.ncbi.nlm.nih.gov/280973056 Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, Bakken S, Kaplan CP, Squiers L, Fabrizio C, Fernandez M. How we design feasibility studies. Am J Prev Med. 2009 May;36(5):452-7. doi: 10.1016/j.amepre.2009.02.002. https://pubmed.ncbi.nlm.nih.gov/193626997 Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available. https://pubmed.ncbi.nlm.nih.gov/293689498 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8. https://pubmed.ncbi.nlm.nih.gov/319129029 Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. https://pubmed.ncbi.nlm.nih.gov/2936894910 Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipović SR, Hummel FC, Jääskeläinen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schönfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014 Nov;125(11):2150-2206. doi: 10.1016/j.clinph.2014.05.021. Epub 2014 Jun 5. Review. https://pubmed.ncbi.nlm.nih.gov/25034472